Evaluation of neurofilament light chain as a biomarker in dogs with structural and idiopathic epilepsy

J Vet Intern Med. 2024 May-Jun;38(3):1577-1582. doi: 10.1111/jvim.17033. Epub 2024 Mar 20.

Abstract

Background: Neurofilament light chain (NfL) is a frequently used biomarker in humans for both diagnostic and therapeutic monitoring purposes in various neurologic diseases.

Hypothesis/objectives: It was hypothesized that dogs with diagnosed structural epilepsy (SE) would have a significantly higher serum NfL concentrations compared to dogs with idiopathic epilepsy (IE). The secondary hypothesis was that dogs would have a significantly higher serum NfL concentrations when measured within 7 days after a seizure compared to being seizure-free for at least 30 days.

Animals: Fifty client-owned dogs presented to the neurology service for evaluation of seizures were enrolled. Fourteen dogs had SE and 36 dogs had IE.

Methods: Prospective cohort study performed on 52 serum samples obtained for NfL concentration measurement using single molecule array technology.

Results: The median serum concentration of NfL in dogs with SE was significantly higher (109 pg/mL; range, 11.4-741.3 pg/mL) than in dogs with IE (17.7 pg/mL; range, 5.8-188 pg/mL; Wilcoxon rank sum test, P = .001). No significant relationship was found between serum NfL concentration and time of sampling in relation to the most recent seizure in dogs with IE.

Conclusions and clinical importance: Serum NfL may serve as an adjunctive biomarker for the differentiation of SE and IE.

Keywords: canine; glioma; neurology; seizure.

MeSH terms

  • Animals
  • Biomarkers* / blood
  • Cohort Studies
  • Dog Diseases* / blood
  • Dog Diseases* / diagnosis
  • Dogs
  • Epilepsy* / blood
  • Epilepsy* / veterinary
  • Female
  • Male
  • Neurofilament Proteins* / blood
  • Prospective Studies

Substances

  • neurofilament protein L